Initiator Pharma set to start dosing of IPED2015 in Phase 1 again

Initiator Pharma A/S, a biotech company that is developing a novel treatment of erectile dysfunction today announced that it will continue the Phase Clinical trials with IPED2015 in the week of the 12thof November.

Screening of healthy subjects for entering into the re-start of the Phase I, First-in-Man study of IPED2015 is ongoing and recruitment goes as planned. Dosing to the first randomised subjects is planned to start in the week of the 12th of Nov.

 We are really looking forward to continue the Phase 1 clinical trial toreach safe and effective dose levelsso we can proceed to the value creating Proof-of-Concept Phase 2 clinical Study’say CEO, Claus Elsborg Olesen.  

For additional information about Initiator Pharma, please contact: 

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035 E-mail: ceo@initiatorpharma.com 

This information is the information that Initiator Pharma is required to disclose under the EU Market Abuse Regulation. The information was provided under the above contact person’s auspices, for publication on October 29, 2018.

About Initiator Pharma

Initiator Pharma is a Biotech company established in Aarhus, Denmark. Its main asset IPED2015 represents a novel treatment paradigm for the treatment of Erectile Dysfunction (ED) and will improve the quality of life for the growing number for patients (and their partners) that do not respond or cannot be treated with the current marketed medication.

About Erectile dysfunction 

Erectile dysfunction is sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. ED affects more than 150 million men worldwide and that number is expected to increase to more than 320 million by 2025, fueled by aging demographics and increasing prevalence of life style diseases such as diabetes. ED patients have decreased quality of life due to various psychosocial factors such as low self-esteem, depression, sadness, anger, frustration, anxiety, relationship problems etc. (Althof, 2002; Shabsigh et al., 1998, Tsai, 2008; Litwin et al., 1998).